openPR Logo
Press release

Registration opens for SMi’s AI in Drug Discovery Conference 2020

10-28-2019 04:49 PM CET | Health & Medicine

Press release from: SMI

AI in Drug Discovery Conference 2020

AI in Drug Discovery Conference 2020

SMi Reports: Registration is open for SMi’s inaugural AI in Drug Discovery conference taking place in London in March 2020.

SMi is delighted to announce the highly anticipated AI in Drug Discovery conference which will commence on 16th-17th March in London. AI machine learning technologies have the potential to reduce drug discovery costs by an estimated US$70 billion over the next decade, and is therefore leading the way to shorter, cheaper and more successful research and development.

Unfortunately, there can be no AI revolution without first tackling data challenges, such as the lack of consistent and quality data. It is critical, therefore, for industry leaders to come together and discuss strategies to overcome this problem and further advance research in drug discovery.

This two-day agenda offers networking opportunities with VPs, heads, managers, directors and scientists within artificial intelligence, machine learning, drug discovery, R&D, medicinal chemistry, cheminformatics, molecular AI and other related industries.

Registration is live on the website and an early bird saving of £400 is available for bookings made before 29st November 2019: www.AI-indrugdiscovery.com/openpr1

Key topics will include:

• Case studies from industry leaders in pharmaceuticals and biotechnology who have incorporated AI into their work.
• How deep learning methods can be used for compound screening, de novo design, multiparameter optimization and more.
• Strategies for overcoming data-related challenges and data access.
• Unique approaches such as fragment-based and network-driven drug discovery.

Key speakers attending:

Chair:

• Alexander Hillisch, Director, Medicinal Chemistry, Head of Computational Chemistry, Bayer

Featured speakers:

• Andrea Pierleoni, Head of Artificial Intelligence, Healx Limited
• Andreas Bender, Lecturer for Molecular Informatics, University of Cambridge
• Andrew Leach, Head of Chemistry Services, EMBL-EBI
• Christian Tyrchan, Teamleader Computational Chemistry, AstraZeneca Sweden
• Christine Richardson, Principal Scientist, Computational Chemistry, Domainex
• Darren Green, Director of Molecular Design, GSK
• Friedemann Schmidt, Senior Scientist, Preclinical Safety, Sanofi
• Friedrich Rippmann, Director, Global Computational Chemistry & Biology, Merck
• Gerhard Hessler, Head of Synthetic Molecular Design, Sanofi
• Govinda Bhisetti, Head of Computational Chemistry, Biogen
• Graham Smith, Senior Medical Chemist, AstraZeneca
• John Overington, Drug Discovery Informatics, Medicines Discovery Catapult

There will also be a post-conference workshop on 18th March:
Practical Application of Predictive Properties in Drug Design

For the full agenda and speaker line-up, the brochure is available to download online. Register at www.AI-indrugdiscovery.com/openpr1

AI in Drug Discovery Conference 2020
16th-17th March 2020
London, UK

--- ENDS –
Contact Information:
For media enquiries, contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 or hsidhu@smi-online.co.uk

45 Curlew Street

About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Registration opens for SMi’s AI in Drug Discovery Conference 2020 here

News-ID: 1857561 • Views:

More Releases from SMI

Workable Strategic Report on Adaptive Learning Platforms Market by Forecast to 2030 With Covered Top Companies: SAS, D2L, DreamBox Learning, Wiley (Knewton)
Workable Strategic Report on Adaptive Learning Platforms Market by Forecast to 2 …
The latest research study released by Stratagem Market Insights on the "Adaptive Learning Platforms Market" with 100+ pages of analysis on business strategy taken up by emerging industry players, geographical scope, market segments, product landscape and price, and cost structure. It also assists in market segmentation according to the industry's latest and upcoming trends to the bottom-most level, topographical markets, and key advancement from both market and technology-aligned perspectives. Each
New Technology Developments in Container Leasing Service Market to Grow during Forecast year 2023-2030 : MC Containers, AB Sea Container, Triton International
New Technology Developments in Container Leasing Service Market to Grow during F …
The latest competent intelligence report published by SMI with the title "An Increase in Demand and Opportunities for Global Container Leasing Service Market 2023" provides a sorted image of the Container Leasing Service industry by analysis of research and information collected from various sources that have the ability to help the decision-makers in the worldwide market to play a significant role in making a gradual impact on the global economy.
Factors Influencing Global Adaptive Digital Learning Tools Market through 2023 and Beyond - Pearson Interactive Labs, Nuance, Querium, Quizlet
Factors Influencing Global Adaptive Digital Learning Tools Market through 2023 a …
Stratagem Market Insights has added a new research study on the Global "Adaptive Digital Learning Tools Market" 2023 by Size, Growth, Trends, and Dynamics, Forecast to 2030 which is a result of an extensive examination of the market patterns. This report covers a comprehensive investigation of the information that influences the market regarding fabricates, business providers, market players, and clients. The report provides data about the aspects which drive the
World Leading Companies involved in The Growing Intellectual Property Protection and Management Service Market 2023 - 2030 | HKPC, 3E Accounting, Keltie, Talal Abu-Ghazaleh Global
World Leading Companies involved in The Growing Intellectual Property Protect …
The "Global Intellectual Property Protection and Management Service Market" research report represents major insights on the current growth dynamics as well as the primary revenue generation elements that are available in the Intellectual Property Protection and Management Service industry along with various other factors over the predicted period 2023-2030. The report on the Intellectual Property Protection and Management Service market is focusing on a series of parameters including top manufacturing

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug